PARKINSON DISEASE (Disorder)Emerge ParkNCT07439926
Description of the Reasons for Hospitalization of Patients With Parkinson's Disease Following Admission Through the Adult Emergency Department
An observational study of PARKINSON DISEASE (Disorder), run by Assistance Publique - Hôpitaux de Paris at 1 site in France.
Trial summary
The goal of this observational study is to investigate the causes of hospitalisation via emergency services in patients with degenerative parkinsonian syndromes. All causes of hospital admission through the emergency department among patients with Parkinson's-related disorders were analysed in order to understand… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- PARKINSON DISEASE (Disorder)
- How many people
- 2,580 participants
- Where
- 1 siteFrance
- Study dates
- 1 Jan 2022to 4 Aug 2025
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Adult patients with or without Parkinson's disease admitted to the emergency departments of the 39 APHP hospitals in France between January 1, 2022, and December 31, 2023. N.B. APHP: Assistance Publique des Hôpitaux de Paris/ Public Assistance Of the Paris Hospitals.
Who may be able to join
- patients with and without a history of neurodegenerative parkinsonian disorders, identified through ICD-10 inpatient coding (codes 'G20', 'G21', 'G22', 'G231', 'G232', 'G233', and 'F023')
- patients who were hospitalised in one of the 39 AP-HP hospitals via an emergency department for a minimum duration of 24 hours
Who cannot join
- patients admitted to the emergency room for less than 24 hours
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Description of the Reasons for Hospitalization of Patients With Parkinson's Disease Following Admission Through the Adult Emergency Department: the Emerge Park Regional Study
The goal of this observational study is to investigate the causes of hospitalisation via emergency services in patients with degenerative parkinsonian syndromes.
All causes of hospital admission through the emergency department among patients with Parkinson's-related disorders were analysed in order to understand their vulnerability and the factors that worsen their health status.
Data from included patients were compared to those of age-matched individuals without Parkinson's disease.
Read the detailed description
The investigators performed a population-based retrospective study using the data from electronic medical records available through the data warehouse of the Greater Paris public hospitals (Entrepôt de Données de Santé (EDS) de l'AP-HP). Our study was reported according to the STROBE statement.
This study was approved and registered by the Ethics committee of the data warehouse (AP-HP CDW Scientific and Ethics Committee) under n°CSE-22-27_Emerge-Park IRB00011591. In accordance with French regulations (loi n° 2018-493 du 20 juin 2018), patients were informed that their medical records may be used for research purposes through an informational notice, and all personal identifiers were pseudonymised during the data extraction process to maintain confidentiality. No written consent was then required for this retrospective study.
The EDS currently collects data on patient's follow-up in the 39 hospitals within the AP-HP across the Île-de-France region. This warehouse contains medico-administrative data from the Medical Information System Program (PMSI), the French national hospital database. The PMSI gathers data from standardized discharge reports that document hospital visits, including diagnoses and the procedures performed in all medical units involved in the patient's care during each hospitalisation. Primary and associated diagnoses are coded using the International Classification of Diseases, 10th Revision (ICD-10). Additionally, the EDS incorporates supplementary data from multiple electronic health record systems, including drug prescriptions - stored within the ORBIS medication database and coded according to the international Anatomical Therapeutic Chemical (ATC) classification system - and medical text reports during hospital visits.
The investigators included patients aged 18 years or older, with a history of neurodegenerative parkinsonian disorders, identified through ICD-10 inpatient coding (codes 'G20', 'G21', 'G22', 'G231', 'G232', 'G233', and 'F023'), who were hospitalised in one of the 39 AP-HP hospitals via an emergency department for a minimum duration of 24 hours, between January 1, 2022, and December 31, 2023 (Fig 1). Patients who presented to the emergency department without being subsequently hospitalised were not included in the study.
To identify non-parkinsonian group patients, the investigators employed the same methodology over the same period, but without identification of an ICD-10 code relative to a parkinsonian disorder.
In a post hoc analysis given the age distribution of parkinsonian patients - with no identified patient under 50 years old and to ensure a more homogeneous population while minimizing selection bias, the investigators chose to include only individuals over 50 years old in the non-parkinsonian cohort.
The primary outcome was the principal diagnosis recorded for each hospitalisation of parkinsonian and non-parkinsonian patients. Each emergency visits that results in hospitalisation was included and considered a unit of analysis for the principal diagnosis for admission. For a single visit, a patient could be hospitalised in multiple units, with each principal diagnosis from each unit being included in the analysis.
For each patient, demographic data were collected at visit time including age, gender, length of hospital stay, number of visits per patient, and inhospital mortality. Patients were re-identified as many times as they had visits, allowing for the assessment of the frequency of emergency visits per patient as a measure of the burden of the disease.
For the analysis, all primary causes of hospitalisations were categorized into specific groups according to the motor and non-motor complications encountered in parkinsonian syndromes on existing literature and ICD-10 classifications, as follows : Neurological disorders, Falls and fractures, Infectious pneumonia, Neuropsychiatric disorders, Urogenital disorders, Constipation-related disorders, General symptoms and malnutrition, Social disability, Other infections, General comorbidities, Other causes of admission, and Sudden death.
The data collected were described using the number and percentage for categorical variables, while continuous variables were expressed as median and interquartile range (IQR).
A differential co-occurrence matrix was constructed to examine the frequency of co-occurring diagnoses between parkinsonian patients and non-parkinsonian subjects. To mitigate class imbalance, the co-occurrence matrix was transformed into percentage form, providing a pseudo-normalized representation of the associations between diagnoses. This transformation ensures that differences in diagnostic co-occurrences are not driven by sample size disparities between groups. The matrix allows for a detailed comparison of the co-occurrence patterns in parkinsonian patients themselves and also compared to non-parkinsonian patients, offering insight into the unique patterns of comorbidity in parkinsonian patients.
A radar plot was created to visualize significant features, providing an illustration that compares the extent of heterogeneity in the parkinsonian and non-parkinsonian groups.
- Conditions
- PARKINSON DISEASE (Disorder)
- Being tested
- No Intervention: Observational Cohort
- Keywords
- parkinson, epidemiology, hospitalisation, vulnerability
- Medical subject headings
- Parkinson Disease
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
No Intervention: Observational CohortOther
no intervention only descriptive analysis
| Study group | Role | What they receive |
|---|---|---|
| emerge park study cohort | Patient with and without parkinsonian related disease Receives: Other: No Intervention: Observational Cohort |
What is being measured
The primary outcome is the main question the study is designed to answer.
To identify the principal diagnosis in patients with Parkinson's disease that lead to emergency admission followed by hospitalization, and compare them with those observed in a population of non-Parkinson's patients.
ICM 10's Code of the principal cause of hospitalisation for each stay of patient after emergency room consultation
Measured: Through study completion, an average of 1 year
Secondary outcomes (5)
To assess the factors associated with the occurrence of hospitalization via the Emergency Department in Parkinson's patients, including: patient age.
Associated factors to the presence of one of the conditions identified in the analysis of the primary endpoint: patient age
Measured: Through study completion, an average of 1 year
To assess the factors associated with the occurrence of hospitalization via the Emergency Department in Parkinson's patients, including: disease duration.
Associated factors to the presence of one of the conditions identified in the analysis of the primary endpoint: disease duration.
Measured: Through study completion, an average of 1 year
To assess the factors associated with the occurrence of hospitalization via the Emergency Department in Parkinson's patients, including: type and dosage of antiparkinsonian treatment.
Associated factors to the presence of one of the conditions identified in the analysis of the primary endpoint: type and dosage of antiparkinsonian treatment
Measured: Through study completion, an average of 1 year
To assess the factors associated with the occurrence of hospitalization via the Emergency Department in Parkinson's patients, including: concomitant non-parkinsonian treatments (e.g., antihypertensive drugs).
Associated factors to the presence of one of the conditions identified in the analysis of the primary endpoint: concomitant non-parkinsonian treatments (e.g., antihypertensive drugs).
Measured: Through study completion, an average of 1 year
To assess the factors associated with the occurrence of hospitalization via the Emergency Department in Parkinson's patients, including: comorbidities.
Associated factors to the presence of one of the conditions identified in the analysis of the primary endpoint: comorbidities.
Measured: Through study completion, an average of 1 year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted27 Feb 2026
- Study start1 Jan 2022
- Primary completion31 Dec 2023
- Study completion4 Aug 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for PARKINSON DISEASE (Disorder)Studies of the same condition, open and under way.
- More trials run by Assistance Publique - Hôpitaux de ParisThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 2,580 participants (actual)
Sponsor and investigators
- Lead sponsor
- Assistance Publique - Hôpitaux de Paris
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07439926
- Sponsor's protocol ID
- IRB0011591
- Acronym
- Emerge Park
- Status last verified
- Sep 2025
- First submitted
- 2 Feb 2026
- Last updated
- 27 Feb 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: data from the data warehouse of the Greater Paris public hospitals can only be extracted in aggregated form, without individual-level data.
Study at a glance
From the registry record, last updated by the sponsor on 27 Feb 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Description of the Reasons for Hospitalization of Patients With Parkinson's Disease Following Admission Through the Adult Emergency Department: the Emerge Park Regional Study
- ClinicalTrials.gov ID
- NCT07439926
- Acronym / sponsor ID
- Emerge Park / IRB0011591
- Conditions
- PARKINSON DISEASE (Disorder)
- Keywords
- parkinson, epidemiology, hospitalisation, vulnerability
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 2,580 participants (actual)
- Lead sponsor
- Assistance Publique - Hôpitaux de ParisUniversity, hospital or other
- Study start
- 1 Jan 2022 (actual)
- Primary completion
- 31 Dec 2023 (actual)
- Study completion
- 4 Aug 2025 (actual)
- First posted
- 27 Feb 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this observational study is to investigate the causes of hospitalisation via emergency services in patients with degenerative parkinsonian syndromes.
All causes of hospital admission through the emergency department among patients with Parkinson's-related disorders were analysed in order to understand their vulnerability and the factors that worsen their health status.
Data from included patients were compared to those of age-matched individuals without Parkinson's disease.
Detailed description
The investigators performed a population-based retrospective study using the data from electronic medical records available through the data warehouse of the Greater Paris public hospitals (Entrepôt de Données de Santé (EDS) de l'AP-HP). Our study was reported according to the STROBE statement.
This study was approved and registered by the Ethics committee of the data warehouse (AP-HP CDW Scientific and Ethics Committee) under n°CSE-22-27_Emerge-Park IRB00011591. In accordance with French regulations (loi n° 2018-493 du 20 juin 2018), patients were informed that their medical records may be used for research purposes through an informational notice, and all personal identifiers were pseudonymised during the data extraction process to maintain confidentiality. No written consent was then required for this retrospective study.
The EDS currently collects data on patient's follow-up in the 39 hospitals within the AP-HP across the Île-de-France region. This warehouse contains medico-administrative data from the Medical Information System Program (PMSI), the French national hospital database. The PMSI gathers data from standardized discharge reports that document hospital visits, including diagnoses and the procedures performed in all medical units involved in the patient's care during each hospitalisation. Primary and associated diagnoses are coded using the International Classification of Diseases, 10th Revision (ICD-10). Additionally, the EDS incorporates supplementary data from multiple electronic health record systems, including drug prescriptions - stored within the ORBIS medication database and coded according to the international Anatomical Therapeutic Chemical (ATC) classification system - and medical text reports during hospital visits.
The investigators included patients aged 18 years or older, with a history of neurodegenerative parkinsonian disorders, identified through ICD-10 inpatient coding (codes 'G20', 'G21', 'G22', 'G231', 'G232', 'G233', and 'F023'), who were hospitalised in one of the 39 AP-HP hospitals via an emergency department for a minimum duration of 24 hours, between January 1, 2022, and December 31, 2023 (Fig 1). Patients who presented to the emergency department without being subsequently hospitalised were not included in the study.
To identify non-parkinsonian group patients, the investigators employed the same methodology over the same period, but without identification of an ICD-10 code relative to a parkinsonian disorder.
In a post hoc analysis given the age distribution of parkinsonian patients - with no identified patient under 50 years old and to ensure a more homogeneous population while minimizing selection bias, the investigators chose to include only individuals over 50 years old in the non-parkinsonian cohort.
The primary outcome was the principal diagnosis recorded for each hospitalisation of parkinsonian and non-parkinsonian patients. Each emergency visits that results in hospitalisation was included and considered a unit of analysis for the principal diagnosis for admission. For a single visit, a patient could be hospitalised in multiple units, with each principal diagnosis from each unit being included in the analysis.
For each patient, demographic data were collected at visit time including age, gender, length of hospital stay, number of visits per patient, and inhospital mortality. Patients were re-identified as many times as they had visits, allowing for the assessment of the frequency of emergency visits per patient as a measure of the burden of the disease.
For the analysis, all primary causes of hospitalisations were categorized into specific groups according to the motor and non-motor complications encountered in parkinsonian syndromes on existing literature and ICD-10 classifications, as follows : Neurological disorders, Falls and fractures, Infectious pneumonia, Neuropsychiatric disorders, Urogenital disorders, Constipation-related disorders, General symptoms and malnutrition, Social disability, Other infections, General comorbidities, Other causes of admission, and Sudden death.
The data collected were described using the number and percentage for categorical variables, while continuous variables were expressed as median and interquartile range (IQR).
A differential co-occurrence matrix was constructed to examine the frequency of co-occurring diagnoses between parkinsonian patients and non-parkinsonian subjects. To mitigate class imbalance, the co-occurrence matrix was transformed into percentage form, providing a pseudo-normalized representation of the associations between diagnoses. This transformation ensures that differences in diagnostic co-occurrences are not driven by sample size disparities between groups. The matrix allows for a detailed comparison of the co-occurrence patterns in parkinsonian patients themselves and also compared to non-parkinsonian patients, offering insight into the unique patterns of comorbidity in parkinsonian patients.
A radar plot was created to visualize significant features, providing an illustration that compares the extent of heterogeneity in the parkinsonian and non-parkinsonian groups.
Study design
- Observational model
- Cohort
- Time perspective
- Retrospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| emerge park study cohort | – | Other: No Intervention: Observational CohortPatient with and without parkinsonian related disease |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Adult patients with or without Parkinson's disease admitted to the emergency departments of the 39 APHP hospitals in France between January 1, 2022, and December 31, 2023. N.B. APHP: Assistance Publique des Hôpitaux de Paris/ Public Assistance Of the Paris Hospitals.
Key inclusion criteria (2 listed)
- patients with and without a history of neurodegenerative parkinsonian disorders, identified through ICD-10 inpatient coding (codes 'G20', 'G21', 'G22', 'G231', 'G232', 'G233', and 'F023')
- patients who were hospitalised in one of the 39 AP-HP hospitals via an emergency department for a minimum duration of 24 hours
Key exclusion criteria (1 listed)
- patients admitted to the emergency room for less than 24 hours
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| No Intervention: Observational Cohortno intervention only descriptive analysis | Other | emerge park study cohort |
Primary outcome
To identify the principal diagnosis in patients with Parkinson's disease that lead to emergency admission followed by hospitalization, and compare them with those observed in a population of non-Parkinson's patients.
Time frame: Through study completion, an average of 1 year
ICM 10's Code of the principal cause of hospitalisation for each stay of patient after emergency room consultation
5 secondary outcomes
To assess the factors associated with the occurrence of hospitalization via the Emergency Department in Parkinson's patients, including: patient age.
Time frame: Through study completion, an average of 1 year
To assess the factors associated with the occurrence of hospitalization via the Emergency Department in Parkinson's patients, including: disease duration.
Time frame: Through study completion, an average of 1 year
To assess the factors associated with the occurrence of hospitalization via the Emergency Department in Parkinson's patients, including: type and dosage of antiparkinsonian treatment.
Time frame: Through study completion, an average of 1 year
To assess the factors associated with the occurrence of hospitalization via the Emergency Department in Parkinson's patients, including: concomitant non-parkinsonian treatments (e.g., antihypertensive drugs).
Time frame: Through study completion, an average of 1 year
To assess the factors associated with the occurrence of hospitalization via the Emergency Department in Parkinson's patients, including: comorbidities.
Time frame: Through study completion, an average of 1 year
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 27 Feb 2026.
- Individual participant dataSharing planned: No. data from the data warehouse of the Greater Paris public hospitals can only be extracted in aggregated form, without individual-level data.
Related trials for PARKINSON DISEASE (Disorder)
Not yet recruitingPhase 1/2
STAR0602 With Nivolumab in Non Small Cell Lung Cancer and in Metastatic Castrate-Resistant Prostate Cancer, and STAR0602 Alone in Thymic Carcinoma
NSCLC, Non-Small Cell Lung Cancer
Enrolling by invitationObservational study
Early Molecular Biomarkers for Differentiating Parkinsonian Syndromes
PARKINSON DISEASE (Disorder), Atypical Parkinsonism
RecruitingPhase 3
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)
Cervical Cancer
Active, not recruitingPhase 1/2
Clinical Safety and Efficacy of Umbilical Cord Mesenchymal Stromal Cells-derived Exosomes in Patients With Parkinson's Disease
Parkinson Disease (PD)
Active, not recruitingObservational study
Adaptive DBS to Offset STN Dysregulation During Exercise in PD
Parkinson Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of PARKINSON DISEASE (Disorder), run by Assistance Publique - Hôpitaux de Paris at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 27 Feb 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
To identify the principal diagnosis in patients with Parkinson's disease that lead to emergency admission followed by hospitalization, and compare them with those observed in a population of non-Parkinson's patients. (time frame: Through study completion, an average of 1 year). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 Feb 2026.